Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fully human anti-tetanus monoclonal antibody
- Development stage
- Unknown
- Lead developer
- MassBiologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
A fully human monoclonal antibody (mAb) designed to neutralize the tetanus toxin produced by *Clostridium tetani*. Unlike traditional human tetanus immune globulin (TIG), which is derived from pooled human plasma and carries risks of supply shortages and blood-borne pathogen transmission, these mAbs are produced via recombinant DNA technology. They typically target the heavy chain of the tetanus toxin, preventing its binding to gangliosides on neuronal membranes and subsequent internalization, thereby blocking the inhibition of neurotransmitter release that causes spastic paralysis. Several candidates, such as Shionogi's S-101 and MassBiologics' TeAb, have been investigated as potential replacements for TIG in post-exposure prophylaxis.
- Other names
- fully human anti-tetanus monoclonal antibodyHuman monoclonal antibody to tetanus toxinAnti-tetanus mAb
02
Targets
TTC (Tetanus neurotoxin heavy chain fragment C)TeNT-Hn (Tetanus neurotoxin heavy chain N-terminal fragment)TeNT-LC (Tetanus neurotoxin light chain)
Beyond the preview
Go deeper on fully human anti-tetanus monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fully human anti-tetanus monoclonal antibody.